STAT3 and neoplasm: In addition, STAT3 inhibitors, including stattic (56) and napabucasin (57, 58), suppressed STAT3 phosphorylation and activation in IL20RB-expressing tumor cells after stimulation by osteoclastic CM or IL-19 (Supplemental Figure 8, D–G), leading to inhibition of organoid formation (Supplemental Figure 8, H and I).